176 related articles for article (PubMed ID: 25300984)
1. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).
Maravilla KR; Smith MP; Vymazal J; Goyal M; Herman M; Baima JJ; Babbel R; Vaneckova M; Žižka J; Colosimo C; Urbańczyk-Zawadzka M; Mechl M; Bag AK; Bastianello S; Bueltmann E; Hirai T; Frattini T; Kirchin MA; Pirovano G
AJNR Am J Neuroradiol; 2015 Jan; 36(1):14-23. PubMed ID: 25300984
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
3. Clinical Efficacy of Reduced-Dose Gadobutrol Versus Standard-Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75).
Liu BP; Rosenberg M; Saverio P; Weon YC; Peters S; Ardellier FD; Boeckenhoff A; Endrikat J
AJR Am J Roentgenol; 2021 Nov; 217(5):1195-1205. PubMed ID: 34133205
[No Abstract] [Full Text] [Related]
4. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).
Seidl Z; Vymazal J; Mechl M; Goyal M; Herman M; Colosimo C; Pasowicz M; Yeung R; Paraniak-Gieszczyk B; Yemen B; Anzalone N; Citterio A; Schneider G; Bastianello S; Ruscalleda J
AJNR Am J Neuroradiol; 2012 Jun; 33(6):1050-8. PubMed ID: 22383237
[TBL] [Abstract][Full Text] [Related]
5. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model.
Robert P; Vives V; Grindel AL; Kremer S; Bierry G; Louin G; Ballet S; Corot C
Radiology; 2020 Jan; 294(1):117-126. PubMed ID: 31660804
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
[TBL] [Abstract][Full Text] [Related]
7. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI.
Kuhl C; Csőszi T; Piskorski W; Miszalski T; Lee JM; Otto PM
Radiology; 2023 Jul; 308(1):e222612. PubMed ID: 37462494
[TBL] [Abstract][Full Text] [Related]
9. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting.
Anzalone N; Scarabino T; Venturi C; Cristaudo C; Tartaro A; Scotti G; Zimatore D; Floris R; Carriero A; Longo M; Cirillo M; Cova MA; Gatti S; Voth M; Colosimo C
Eur J Radiol; 2013 Jan; 82(1):139-45. PubMed ID: 21890295
[TBL] [Abstract][Full Text] [Related]
10. Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read.
Koenig M; Schulte-Altedorneburg G; Piontek M; Hentsch A; Spangenberg P; Schwenke C; Harders A; Heuser L
Eur Radiol; 2013 Dec; 23(12):3287-95. PubMed ID: 23824152
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study.
Gutierrez JE; Rosenberg M; Seemann J; Breuer J; Haverstock D; Agris J; Balzer T; Anzalone N
Magn Reson Insights; 2015; 8():1-10. PubMed ID: 25922578
[TBL] [Abstract][Full Text] [Related]
12. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide.
Rowley HA; Scialfa G; Gao PY; Maldjian JA; Hassell D; Kuhn MJ; Wippold FJ; Gallucci M; Bowen BC; Schmalfuss IM; Ruscalleda J; Bastianello S; Colosimo C
AJNR Am J Neuroradiol; 2008 Oct; 29(9):1684-91. PubMed ID: 18599575
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study).
Maravilla KR; San-Juan D; Kim SJ; Elizondo-Riojas G; Fink JR; Escobar W; Bag A; Roberts DR; Hao J; Pitrou C; Tsiouris AJ; Herskovits E; Fiebach JB
AJNR Am J Neuroradiol; 2017 Sep; 38(9):1681-1688. PubMed ID: 28663267
[TBL] [Abstract][Full Text] [Related]
14. The TRUTH confirmed: validation of an intraindividual comparison of gadobutrol and gadoteridol for imaging of glioblastoma using quantitative enhancement analysis.
Kuhn MJ; Patriarche JW; Patriarche D; Kirchin MA; Bona M; Pirovano G
Eur Radiol Exp; 2021 Oct; 5(1):46. PubMed ID: 34635965
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: intraindividual comparison with double-dose gadopentetate dimeglumine.
Kim ES; Chang JH; Choi HS; Kim J; Lee SK
AJNR Am J Neuroradiol; 2010 Jun; 31(6):1055-8. PubMed ID: 20110372
[TBL] [Abstract][Full Text] [Related]
16. Inter-individual Comparison of Gadobutrol and Gadoteridol Tissue Time-intensity Profiles for Dynamic Susceptibility Contrast Perfusion MR Imaging.
Yamada M; Taoka T; Kawaguchi A; Yasuda K; Niinomi Y; Ohashi Y; Okuda T; Naganawa S
Magn Reson Med Sci; 2019 Jan; 18(1):75-81. PubMed ID: 29794406
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention.
Kuhn MJ; Picozzi P; Maldjian JA; Schmalfuss IM; Maravilla KR; Bowen BC; Wippold FJ; Runge VM; Knopp MV; Wolansky LJ; Gustafsson L; Essig M; Anzalone N
J Neurosurg; 2007 Apr; 106(4):557-66. PubMed ID: 17432704
[TBL] [Abstract][Full Text] [Related]
18. Comparison of gadoteric acid and gadobutrol for detection as well as morphologic and dynamic characterization of lesions on breast dynamic contrast-enhanced magnetic resonance imaging.
Renz DM; Durmus T; Böttcher J; Taupitz M; Diekmann F; Huppertz A; Pfeil A; Maurer MH; Streitparth F; Bick U; Hamm B; Fallenberg EM
Invest Radiol; 2014 Jul; 49(7):474-84. PubMed ID: 24637587
[TBL] [Abstract][Full Text] [Related]
19. Focal liver lesions: detection and characterization at double-contrast liver MR Imaging with ferucarbotran and gadobutrol versus single-contrast liver MR imaging.
Heilmaier C; Lutz AM; Bolog N; Weishaupt D; Seifert B; Willmann JK
Radiology; 2009 Dec; 253(3):724-33. PubMed ID: 19789232
[TBL] [Abstract][Full Text] [Related]
20. The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study).
Vaneckova M; Herman M; Smith MP; Mechl M; Maravilla KR; Weichet J; Spampinato MV; Žižka J; Wippold FJ; Baima JJ; Babbel R; Bültmann E; Huang RY; Buhk JH; Bonafé A; Colosimo C; Lui S; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJNR Am J Neuroradiol; 2015 Sep; 36(9):1589-98. PubMed ID: 26185325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
